LivaNova PLC

Listed Company

LIVNCIK 0001639691NasdaqLarge AcceleratedElectromedical & Electrotherapeutic ApparatusX0GBFY ends Dec 31

Period

FY 2025

Revenue

$1.39B

Net Income

$-242.47M

Total Assets

$2.61B

Equity

$1.20B

Shares Out

54.69M

Op. Cash Flow

$254.34M

Business

LivaNova PLC designs, develops, manufactures, markets, and sells medical devices and therapies for select neurological and cardiac conditions. The Company’s main products include heart-lung machines, oxygenators, perfusion tubing, autotransfusion systems, cannulae, and the VNS Therapy and aura6000 neuromodulation systems. LivaNova reports two primary business segments: Cardiopulmonary and Neuromodulation, with an Other category for corporate items and legacy operations. The Company distributes products globally through direct sales representatives, agents, and independent distributors, serving hospitals, perfusionists, neurologists, neurosurgeons, and other healthcare providers across major international regions.

Summary from filing dated 2025-02-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net revenue	1,388	1,253	1,154	1,022	1,035
Cost of sales	448	400	398	315	329
Gross profit	940	853	756	707	706
Selling, general, and administrative	549	509	503	469	472
Research and development	186	183	194	156	183
Impairment of long-lived assets	0	0	90	0	0
Other operating expense	6	33	38	30	51
Operating income (loss)	199	129	−68	−77	−784,000
SNIA environmental liability expense	−366	0	0	—	—
Interest expense	−49	−63	−59	−48	—
Loss on debt extinguishment	−3	−26	0	0	−60
Foreign exchange and other income/(expense)	−3	48	46	—	—
(Loss) income before income tax	−221	88	−81	−75	−124
Income tax expense (benefit)	22	25	−99	11	11
Loss from equity method investments	−51,000	−18,000	−104,000	−53,000	−148,000
Net (loss) income	−242	63	18	−86	−136
Basic (loss) income per share (in dollars per share)	−4.45	1.17	0.33	−1.61	−2.68
Diluted (loss) income per share (in dollars per share)	−4.45	1.16	0.32	−1.61	−2.68
Shares used in computing basic (loss) income per share (in shares)	55	54	54	53	51
Shares used in computing diluted (loss) income per share (in shares)	55	55	54	53	51

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	636	429	267	214	208
Restricted cash	0	295	311	301	0
Accounts receivable, net of allowance of $12,527 as of December 31, 2025 and $11,275 as of December 31, 2024	216	193	215	183	185
Inventories	165	148	148	129	106
Prepaid and refundable taxes	49	31	20	32	38
Prepaid expenses and other current assets	37	32	27	26	36
Total Current Assets	1,102	1,127	988	886	679
Property, plant, and equipment, net	243	170	154	147	150
Goodwill	793	750	783	769	900
Intangible assets, net	230	237	261	369	400
Operating lease assets	56	47	51	36	41
Investments	20	25	—	—	—
Deferred tax assets	111	112	119	1	2
Long-term derivative assets	37	24	38	54	0
Other assets	16	14	12	16	13
Total Assets	2,606	2,506	2,430	2,295	2,201
Current debt obligations	31	78	18	23	230
Accounts payable	97	70	81	74	68
Accrued liabilities and other	95	118	107	81	89
SNIA environmental liability	396	0	—	—	—
Current contingent consideration	50	0	—	—	—
Current litigation provision liability	13	13	11	29	33
Taxes payable	33	32	23	17	15
Accrued employee compensation and related benefits	93	81	95	72	79
Total Current Liabilities	808	392	335	297	697
Long-term debt obligations	345	550	569	518	10
Long-term contingent consideration	42	84	81	85	—
Deferred tax liabilities	10	11	12	9	8
Long-term operating lease liabilities	48	40	45	30	36
Long-term employee compensation and related benefits	14	13	17	17	19
Long-term derivative liabilities	84	52	46	86	0
Other long-term liabilities	55	44	48	46	50
Total Liabilities	1,406	1,186	1,152	1,087	906
Commitments and contingencies (Note 11)	—	—	—	—	—
Ordinary Shares, 1.00 par value: Unlimited shares authorized; 55,535,181 shares issued and 54,649,085 shares outstanding as of December 31, 2025; 54,437,670 shares issued and 54,348,542 shares outstanding as of December 31, 2024	85	83	83	82	82
Additional paid-in capital	2,255	2,221	2,190	2,158	2,118
Accumulated other comprehensive income (loss)	7	−80	−28	−48	−7
Accumulated deficit	−1,146	−903	−966	−984	−898
Treasury shares at cost, 886,096 ordinary shares as of December 31, 2025; 89,128 ordinary shares as of December 31, 2024	−1	−136,000	—	—	—
Total Shareholders Equity	1,200	1,320	1,278	1,208	1,295
Total Liabilities and Shareholders Equity	2,606	2,506	2,430	2,295	2,201

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Share-based compensation	36	34	36	45	41
Depreciation	29	25	25	22	25
Amortization of debt issuance costs	23	22	19	21	17
Amortization	18	17	25	—	—
Amortization of operating lease assets	13	9	11	10	17
Remeasurement of contingent consideration to fair value	8	3	9	−30	564,000
Remeasurement of derivative instruments, net	−7	−25	−23	−39	18
Gain on sale of asset	−4	0	0	—	—
Loss (gain) on investment revaluation - Ceribell, Inc.	4	−7	0	0	—
Deferred income tax expense (benefit)	455,000	7	−114	1	3
Impairment of investments	1	6	0	—	—
ACS inventory obsolescence adjustment	0	0	13	0	0
Other	3	3	1	2	717,000
Accounts receivable, net	−11	11	−29	−5	−16
Inventories	−5	−7	−28	−26	4
Other current and non-current assets	39	−2	15	7	24
Accounts payable and accrued current and non-current liabilities	−13	−14	19	−4	13
Taxes payable	−4	11	7	1	103,000
SNIA environmental liability	366	0	0	—	—
Litigation provision liability	−1	2	−19	−7	3
Net cash provided by operating activities	254	183	75	70	103
Purchases of property, plant, and equipment	−81	−47	−35	−27	−25
Proceeds from sale of investment	7	0	0	—	—
Proceeds from asset sales	7	89,000	1	—	—
Purchases of investments	−6	−1	−7	−3	−4
Net cash used in investing activities	−73	−48	−40	−38	37
Repayment of long-term debt obligations	−281	−248	−22	−224	−452
Shares repurchased from employees for minimum tax withholding	−4	−8	−8	−9	−13
Proceeds from exercise of stock options	35,000	6	19,000	645,000	—
Proceeds from long-term debt obligations	0	336	50	508	0
Payment of debt extinguishment costs	0	−39	0	0	—
Purchase of capped calls	0	−32	0	0	0
Proceeds from unwind of capped calls	0	23	0	0	—
Payment of contingent consideration	0	−14	0	0	−5
Payment of debt issuance costs	0	−6	0	−3	−2
Other	−338,000	438,000	592,000	3	4
Net cash (used in) provided by financing activities	−286	19	21	280	−181
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	16	−8	6	−4	−3
Net (decrease) increase in cash, cash equivalents, and restricted cash	−88	146	62	308	−45

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro